Pathologic Staging of Endometrial Carcinomas: Selected Areas of Difficulty
This review addresses challenges in pathologically staging endometrial carcinomas, including myometrial invasion, adenomyosis, cervical/serosal involvement, lymphovascular invasion, and distinguishing synchronous from metastatic tumors.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (68)
- CD10 imunostaining does not distinguish endometrial carcinoma invading myometrium from carcinoma involving adenomyosis via openalex
- Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma via openalex
- Endometrial adenocarcinoma with variable-level myometrial involvement limited to adenomyosis: a clinicopathologic study of 23 cases via openalex
- Histologic artifacts in abdominal, vaginal, laparoscopic, and robotic hysterectomy specimens: a blinded, retrospective review via openalex
- Interinstitutional surgical pathology review in gynecologic oncology: II. Endometrial cancer in hysterectomy specimens via openalex
- Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion via openalex
- Patterns of myoinvasion in endometrial adenocarcinoma: recognition and implications via openalex
- The role of CD10 staining in distinguishing invasive endometrial adenocarcinoma from adenocarcinoma involving adenomyosis via openalex
- The significance of tumor involved adenomyosis in otherwise low-stage endometrioid adenocarcinoma via openalex
- W2009295317 via openalex
- W2009568211 via openalex
- W2014351071 via openalex
- W2018444080 via openalex
- W2024917007 via openalex
- W2027047465 via openalex
- W2027862992 via openalex
- W2028017661 via openalex
- W2031222466 via openalex
- W2034540330 via openalex
- W2040034181 via openalex
- W2043128771 via openalex
- W2043716184 via openalex
- W2051315066 via openalex
- W2053251794 via openalex
- W2053378161 via openalex
- W2057454630 via openalex
- W2059792082 via openalex
- W2061265681 via openalex
- W2061766462 via openalex
- W2065992785 via openalex
- W2068454208 via openalex
- W2073107213 via openalex
- W2073273317 via openalex
- W2083896827 via openalex
- W2088084613 via openalex
- W2088939235 via openalex
- W2092919115 via openalex
- W2093072907 via openalex
- W2100164970 via openalex
- W2103440320 via openalex
- W2108270268 via openalex
- W2113415002 via openalex
- W2118439294 via openalex
- W2161570950 via openalex
- W2171871964 via openalex
- W2270264837 via openalex
- W2319827626 via openalex
- W2326465893 via openalex
- W2334962328 via openalex
- W2337786508 via openalex
- W2397380511 via openalex
- W2530525054 via openalex
- W2536270877 via openalex
- W4233277036 via openalex
- W4238205485 via openalex
- W4246768807 via openalex
- W4250414578 via openalex
- W6600231419 via openalex
- W5509621 via openalex
- W6628196416 via openalex
- W1438891086 via openalex
- W1903539786 via openalex
- W1922206815 via openalex
- W1968940509 via openalex
- W1982817989 via openalex
- W1984497229 via openalex
- W1994734608 via openalex
- W2004518483 via openalex
Cited by (2)
Source provenance
- europepmc
- last seen: 2026-10-12T06:17:10.165071+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-10-08T21:21:15.855055+00:00
- unpaywall
- last seen: 2026-10-12T06:33:14.382917+00:00